Christina H Sherrill

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Clinical Practice

Stem Cell Transplantation

Top Venues

The Annals of pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Courtney L Bradley, Sara M McMillin, Andrew Y Hwang, Christina H Sherrill
Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. The Annals of pharmacotherapy 58 (4) (2024)
Courtney L Bradley, Sara M McMillin, Andrew Y Hwang, Christina H Sherrill
Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. The Annals of pharmacotherapy 58 (4) (2024)
Courtney L Bradley, Sara M McMillin, Andrew Y Hwang, Christina H Sherrill
Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. The Annals of pharmacotherapy 58 (4) (2024)
Courtney L Bradley, Sara M McMillin, Andrew Y Hwang, Christina H Sherrill
Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. The Annals of pharmacotherapy (2024)
Courtney L Bradley, Sara M McMillin, Andrew Y Hwang, Christina H Sherrill
Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. The Annals of pharmacotherapy 58 (4) (2024)
Christina H Sherrill, Andrew Y Hwang
Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020. The Annals of pharmacotherapy (2023)
Courtney L Bradley, Sara M McMillin, Andrew Y Hwang, Christina H Sherrill
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. The Annals of pharmacotherapy (2022)
Courtney L Bradley, Sara M McMillin, Andrew Y Hwang, Christina H Sherrill
High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management. The Annals of pharmacotherapy (2021)